anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Anaemia is a frequent complication of chronic kidney disease; if severe and untreated, it leads to a worsening of quality of life and an increased risk of resorting to haemotransfusions. Beginning with studies in physio-pathology that began in the late 19th century and continued into the 20th century, the first step was the identification of erythropoietin, then its purification, identification of the gene involved and finally the synthesis of recombinant human erythropoietin and its 'long-acting' analogues. Today, therapy with erythropoiesis-stimulating agents (ESAs), often in combination with martial therapy, is the standard of care for patients with chronic kidney disease and anaemia. Recently, ESAs have been joined by HIF-PHD inhibitors. Unfortunately, both categories of drugs, although effective and well-tolerated in most cases, may be associated with a possible increased cardiovascular and thrombotic risk, especially in particular categories of patients. For this reason, the choice of therapy with ESA and HIF-PHD must be customised in terms of haemoglobin target, molecule type and dosage to be used.
Subjects in this group received 1 dose of Boostrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
Educational method of group treatment based on regular meals and food based on Nordic nutrition recommendations. The method has been developed by a district nurse at Ljungby. Ten meetings in groups of 6-8 participants over 6 months. Group meeting number 5 includes short individual consultations. In addition, individual consultation after group meeting 1 and 10.
The patients will receive isocaloric carbohydrate supplements twice daily (2x21g) for a period of 6 weeks during morning and afternoon. The supplement will be delivered in powdered form.
PURPOSE OF REVIEW: To provide an overview of (a) protective effects on mitochondria induced by remote ischemic conditioning (RIC) and (b) mitochondrial damage caused by anticancer therapy. We then discuss the available results of studies on mitochondrial protection via RIC in anticancer therapy-induced cardiotoxicity.
RECENT FINDINGS: In three experimental studies in healthy mice and pigs, there was a RIC-mediated protection against anthracycline-induced cardiotoxicity and there was some evidence of improved mitochondrial function with RIC. The RIC-mediated protection was not confirmed in the two available studies in cancer patients. In adult cancer patients, RIC was associated with an adverse outcome. There are no data on mitochondrial function in cancer patients. Studies in tumor-bearing animals are needed to determine whether RIC does not interfere with the anticancer properties of the drugs and whether RIC actually improves mitochondrial function, ultimately resulting in improved cardiac function.
The present invention discloses an alpha-linolenic acid enriched functional feed additive which relates to the field of animal nutrition. The alpha-linolenic acid enriched functional feed additive is a functional feed additive for beginning with feed for appropriate nutrition regulation to promote the production performance of animals and is formed by the synthesis of cannabis fruit, glycyrrhiza extract byproducts, barley malt, astragalus root, cynomorium, wolfberry fruit and vitamin E according to a certain proportion. In the basic method for making the alpha-linolenic acid enriched functional feed additive, plant kernels in which the alpha-linolenic acid (alpha-C<18: 3>) is enriched are added in the feed and an amount of Chinese herbal medicine is compounded for promotion. The present invention mainly aims to improve the composition situation of fatty acid, reduce the content of harmful fatty acid and enhance the contents of beneficial fatty acid, protein, etc. under the premise of maintaining or enhancing the yield of an original product. The present invention has the goals that for dairy cows, the basic quality of milk can be quickly improved and enhanced; for store pigs, the production performance is promoted, and the fat metabolism and the carcass quality are improved.
The invention relates to a new technology for conveying a natural antioxidant resveratrol by large aperture starch-containing particles. A biological enzyme technology is adopted as the new technology for preparing the large aperture starch-containing particles as a micro-molecular active substance conveying carrier. The large aperture starch-containing particles are highly inclusive to micro-molecular substances, and the micro-molecular substances can be added to the inner cavities of the large aperture starch-containing particles. Sodium alginate is adopted to microencapsulate the above filler in order to prepare microcapsules. An electron microscope observation result show that the microcapsules have the advantages of uniform appearance, smooth surface and stable form, and an infrared spectroscopic analysis result of the above microencapsulate substance shows that the large aperture starch is successfully microencapsulate by sodium alginate. A result of the reaches of the in vitro metabolism characteristic of the microencapsulate particles by testing the microencapsulating effect and the release rate of the micro-molecular active substance shows that the above conveying system has a high bearing ability on the micro-molecular substances and a slow release rate. The technology adopts green raw materials and a green processing technique in the whole course, so a new approach is provided for the deep processing of starch, and it is possible to convey natural micro-molecular substances.
Decreased levels of β-hydroxybutyrate (BHB), a lipid metabolic intermediate known to slow the progression of colorectal cancer (CRC), have been observed in the colon mucosa of patients with inflammatory bowel diseases (IBD). In particular, patients with recurrent IBD present an increased risk of developing colitis-associated colorectal cancer (CAC). The role and molecular mechanism of BHB in the inflammatory and carcinogenic process of CAC remains unclear. Here, the anti-tumor effect of BHB was investigated in the Azoxymethane (AOM)/Dextran Sulfate Sodium (DSS)-induced CAC model and tumor organoids derivatives. The underlying mechanisms were studied using transcriptome and non-target metabolomic assay and further validated in colon tumor cell lineage CT26 in vitro. The tumor tissues and the nearby non-malignant tissues from colon cancer patients were collected to measure the expression levels of ketogenic enzymes. The exogenous BHB supplement lightened tumor burden and angiogenesis in the CAC model. Notably, transcriptome analysis revealed that BHB effectively decreased the expression of VEGFA in the CAC tumor mucosa. In vitro, BHB directly reduced VEGFA expression in hypoxic-treated CT26 cells by targeting transcriptional factor HIF-1α. Conversely, the deletion of HIF-1α largely reversed the inhibitory effect of BHB on CAC tumorigenesis. Additionally, decreased expression of ketogenesis-related enzymes in tumor tissues were associated with poor survival outcomes in patients with colon cancer. In summary, BHB carries out anti-angiogenic activity in CAC by regulating HIF-1α/VEGFA signaling. These findings emphasize the role of BHB in CAC and may provide novel perspectives for the prevention and treatment of colonic tumors.
The dietary supplement for wellness includes in a combination of L-arginine, ginseng, ginkgo biloba and damiana. The unit dosage is in a capsule or a tablet form or as an aqueous composition. The unit dosage may include an amount of antioxidant vitamins, vitamin B complex, and minerals sufficient to provide up to about 100% to about 200% of the percent daily values of the antioxidant vitamins, vitamin B complex, and minerals upon administering an appropriate quantity of the unit dosages to achieve a desired daily dosage. The daily dosage may be in an amount of up to about 600 ml. of an aqueous composition and may be administered as a beverage. The composition may be administered daily to a subject for a time sufficient for sexually arousing the subject more easily than without administration of the combination. The daily dosage is administered to the subject for a time sufficient to improve the quality of orgasm for the subject and/or to improve the frequency of desire to engage in sexual activity.
<P>PROBLEM TO BE SOLVED: To manufacture resin particles (such as spherical resin particles) having the same particle size by a simple method.  <P>SOLUTION: A resin composition is comprised of a meltable organic solid component (such as a resin component) (A) and a water-soluble auxiliary component (B) containing at least an oligosaccharide (B1). The organic solid component (A) and the auxiliary component (B) have a different surface tension and/or the same or different melt viscosity at the melt-kneading temperature of the resin composition. The resin composition is melt-kneaded to form a dispersion comprising a dispersed phase of the granular organic solid component (A) and a matrix of the auxiliary component (B), and the auxiliary component (B) is caused to be eluted from the dispersion to give particles (such as spherical resin particles) comprising the organic solid component (A). The variation coefficient of the average particle size of the dispersed phase or the particles (such as resin particles) can be 60% or less.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
A feed additive capable of preventing and treating poultry bacterium and virus infectious diseases is provided. Raw materials of the feed additive comprise honeysuckle flower stems and leaves. The feed additive has advantages of capability of preventing and treating bacterium and virus infectious diseases, capability of avoiding use of antibiotic medicines, no medicine residue, no drug resistance and no side or toxic effects. A preparing process of the feed additive is simple, low in energy consumption, pollution-free, safe and convenient. The feed additive is easy to store and has definite medicine effects. Industrialization can be achieved easily. The feed additive has good economic benefit and social benefit.
INTRODUCTION: The purpose of this scoping review was to investigate in the literature how a learning health system (LHS) can be implemented in cases of complex, costly, chronic (3C) conditions.
METHODS: A scoping review of literature published in English since 2007 was conducted using Medline, Cumulative Index to Nursing and Allied Health Literature, and Scopus. Two authors screened the resulting articles and two authors extracted study details on the structure, process, and outcome of each LHS. Eligibility criteria included studies of LHSs that focused on populations experiencing a complex chronic health condition. A narrative synthesis of data was conducted using deductive qualitative methods.
RESULTS: Application of the authors' search strategy resulted in 656 publications that were analyzed for this review. The authors included 17 studies that focused on 13 LHSs. The structure of the LHSs had many components, and many included data from either patient surveys or patient charts. The processes varied widely, from engaging patients in the process to exclusively analyzing the data. The outcomes were largely patient-reported, though several clinical outcomes were also used to benchmark the success of the LHS.
DISCUSSION: Our review shows that LHS definitions, structures, processes, and outcomes in 3C applications vary widely. Many have shown substantial potential to be implemented and improve care in 3C populations. To deliver on this goal, future work will need to focus on better specification, formalization, and definition of LHS approaches, as well as better design of their structures, processes, and outcomes to fit the needs of the intended population.
There is growing evidence that autoantibodies (AAbs) against proteins expressed in the brain are playing an important role in neurological and psychiatric disorders. Here, we explore the presence and the role of peripheral AAbs to the α7-nicotinic acetylcholine receptor (nAChR) in inflammatory subgroups of psychiatric patients with bipolar disorder (BD) or schizophrenia (SCZ) and healthy controls. We have identified a continuum of AAb levels in serum when employing a novel ELISA technique, with a significant elevation in patients compared to controls. Using unsupervised two-step clustering to stratify all the subjects according to their immuno-inflammatory background, we delineate one subgroup consisting solely of psychiatric patients with severe symptoms, high inflammatory profile, and significantly increased levels of anti-nAChR AAbs. In this context, we have used monoclonal mouse anti-human α7-nAChR antibodies (α7-nAChR-mAbs) and shown that TNF-α release was enhanced upon LPS stimulation in macrophages pre-incubated with α7-nAChR-mAbs compared to the use of an isotype control. These findings provide a basis for further study of circulating nicotinic AAbs, and the inflammatory profile observed in patients with major mood and psychotic disorders.
The invention discloses a multi-drug resistant Kentucky salmonella virulent phage and a preparation method and application thereof. The phage name is Salmonella phage (Salmonella phage) MDASK, accession number is GDMCC NO:62376-B1 was stored at 4.12 days 2022 in Guangdong province microorganism strain collection center of No. 5 building of No. 59 of No. 5 of 100 university of Mitsui, guangzhou City. The phage can be obtained by taking multi-drug resistant Kentucky Salmonella (Salmonella sp.Kentucky) 10A20 as a host bacterium for separation, has higher temperature tolerance, wider acid-base tolerance range, high titer, shorter incubation period and strong cracking effect, and can be used as an antibacterial agent for reducing pollution of the Kentucky Salmonella in livestock and poultry production chains.
BACKGROUND: In recent years, certain body composition measures, assessed by computed tomography (CT), have been found to be associated with chemotherapy toxicities. This review aims to explore available data on the relationship between skeletal muscle and adiposity, including visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), intramuscular and intermuscular adipose tissue and their association with chemotherapy toxicity in non-metastatic colorectal cancer (CRC) patients.
METHODS: A systematic literature search following PRISMA guidelines was conducted in Medline, Embase, Cochrane and Web of Science, for papers published between 2011 and 2023. The search strategy combined keywords and MESH terms relevant to 'body composition', 'chemotherapy toxicities', and 'non-metastatic colorectal cancer'.
RESULTS: Out of 3868 studies identified, six retrospective studies fulfilled the inclusion criteria with 1024 eligible patients. Low skeletal muscle mass was strongly associated with increased incidence of both chemotherapy toxicities and dose-limiting toxicity (DLT). The association of VAT, intramuscular and intermuscular adiposity was heterogeneous and inconclusive. There was no association between SAT and chemotherapy intolerance. No universal definitions or cut-offs for sarcopenia and obesity were noted. All studies utilized 2-dimensional (2D) CT slices for CT body composition assessment with varied selection on the vertebral landmark and inconsistent reporting of tissue-defining Hounsfield unit (HU) measurements.
CONCLUSION: Low skeletal muscle is associated with chemotherapy toxicities in non-metastatic CRC. However, quality evidence on the role of adiposity is limited and heterogeneous. More studies are needed to confirm these associations with an emphasis on a more coherent body composition definition and an approach to its assessment, especially regarding sarcopenia.
Obstructive sleep apnea (OSA) is an increasingly prevalent condition that is characterized by repetitive upper airway obstructions. OSA has been independently associated with insulin resistance, suggesting that OSA may contribute to the development of type 2 diabetes and the metabolic syndrome. Recently, postprandial glucose and lipid have been reported as excellent predictors for mortality and cardiovascular risk. However, the association between postprandial glucose, lipid metabolism and OSA are not clear. In addition, humoral factors such as ghrelin and leptin are associated with obesity and OSA, but postprandial changes of which in patients with OSA are not well known. The aim of present study is to examine postprandial glucose and lipid metabolism, humoral factors in OSA before and after 3 months of continuous positive airway pressure (CPAP) treatment.
There is increasing evidence that nonsteroidal and cholesterol lowering medications may be associated with a delay in the onset of Alzheimer's disease (AD). There is separate evidence that beta-amyloid(1-42) is involved in the pathophysiology of AD and levels of beta-amyloid(1-42) in the cerebrospinal fluid (CSF) of AD patients are significantly lower than that found in controls. It has been suggested that these standard medications may have indirect effects that alter the normal course of AD, but there is no data to directly support this contention in humans. Based on previous work, it is our hypothesis that CSF beta-amyloid(1-42) levels may serve as an early biomarker of AD. Any pharmacological induced change in CSF beta-amyloid(1-42) might have profound implications for the eventual onset of illness. Therefore, the purpose of this study is to evaluate the short-term effects of two commonly prescribed nonsteroidal and cholesterol lowering medications, ibuprofen and lovastatin, on the levels of cerebrospinal fluid beta-amyloid(1-42) in a group of normal controls 'at risk' for developing AD.
PURPOSE: Many older dogs (Canis lupus familiaris) develop cognitive impairment. Dog owners often describe impairments in multiple sensory functions, yet the relationships between sensory and cognitive function in older dogs is not well understood.
METHODS: We performed assessments of dog vision and hearing, both clinically (n = 91, electroretinography and brainstem auditory evoked potential) and via validated questionnaire (n = 238). We determined prevalence of sole and dual hearing/vision impairments in younger (<8 years) and older (≥8 years) dogs. Impairment cutoffs were determined using data from young dogs. We assessed the relationships between questionnaire-assessed vision and/or hearing impairments and cognitive impairment using logistic regression.
RESULTS: Younger and older dog groups had similar distributions of sex and purebred/mixed breed status. Sex had no relationship to prevalence of sensory impairments. Older dogs had higher prevalence of hearing, vision, and dual sensory impairments, assessed both clinically and by questionnaire (P<0.001), and cognitive impairment assessed by questionnaire (P<0.001). Dogs had higher prevalence of reported cognitive impairment when owners reported dual vision and hearing impairments (79-94%, versus 25-27% in dogs with no sensory impairments), which was most consistent in dogs aged ≥8 years. In these older dogs, dual vision/hearing impairments were associated with a significantly increased risk of cognitive impairment (1.8-2.0 odds ratio).
CONCLUSION: Dogs aged ≥8 years are at higher risk for dual hearing/vision impairments and associated cognitive impairments. The causal relationship between these impairments is not defined, but clinical consideration of these multimorbidity risks should be made in older dogs.
PROBLEM TO BE SOLVED: To optically characterize 'lift makeup' and 'defocus makeup' by comparing the characteristics of reflected light for a plurality of incident angles with a different angle, and by evaluating powder and/or a powder composition based on the characteristics. SOLUTION: In the evaluation method of powder/a powder composition, the characteristics of reflected light for at least two kinds of incident angles with a different angle are compared. In this case, as the different angle, low and high angles are preferably selected for a line being vertical to a plane for creating a sample. In this case, the low angle means an angle that is close to the line being vertical to the plane being created by the sample and the high angle means an angle that is close to a horizontal surface. As a preferable angle, the lower angle is set to 10 to 30 degrees, more preferably, 15 to 25 degrees, for the line being vertical to the plane created by the sample. The high angle is set to 60 to 90 degrees, more preferably, 70 to 80 degrees. The difference between the low and high angles is preferably set to 40 to 60 degrees.
Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, some are obtained by treating the fermentation products using the method of chemical synthesis or they are the products of total chemical synthesis. The purity of the active ingredient is an important factor for manufacturing the safe and effective pharmaceutical, especially if the pharmaceutical product must be taken on a longer term basis in the treatment or prevention of high plasma cholesterol. The accumulation of the impurities from the pharmaceuticals of lower purity may cause many side effects during the medical treatment. The present invention relates to a new industrial process for the isolation of HMG-CoA reductase inhibitors using so-called displacement chromatography. Use of the invention enables to obtain HMG-CoA reductase inhibitors of high purity, with high yields, lower production costs and suitable ecological balance.
Systems, methods, and devices model, identify, and predict effects of dialysis on drugs and chemical substances in patients. The systems estimate and determine effects of dialysis on elutes and drugs and solve problems with prior systems in determining effects of dialysis on drugs and dosages, especially the removal of target substances from the blood of patients during dialysis. Drug and medicine dosage adjustments for patients undergoing dialysis are made by considering the dialysis systems, patients, and drug variables and the extent to which they affect drug removal. Patients receive proper dosing by accounting for the effects of their dialysis. Systems and methods include a combination of ex vivo simulated treatments and in-silico modeling and simulation. The effects of dialysis are estimated and determined for various drugs and dosages. A reliable and effective surrogate for performing studies on patients provides guidance for use of the drugs in dialysis patients.
A method, system and article of manufacture for intelligence building in expert systems and, more particularly, for evaluating treatment decisions overriding recommended treatments that are generated by expert systems. One embodiment provides a method of evaluating treatment decisions, comprising receiving a specification of a decided treatment for a patient having a given disease. The decided treatment differs from a recommended treatment identified by an expert system in response to analysis of symptomatic data corresponding to the patient. The patient is monitored subsequent to being treated according to the decided treatment. The decided treatment is evaluated on the basis of data captured by the monitoring. On the basis of the evaluation, feedback with respect to the decided treatment and the recommended treatment is generated.